Rono Charles K, Darkwa James, Meyer Debra, Makhubela Banothile C E
Department of Chemistry, University of Johannesburg, Kingsway Campus, 2006, Auckland Park, South Africa.
Department of Biochemistry, University of Johannesburg, Kingsway Campus, 2006, Auckland Park, South Africa.
Curr Org Synth. 2019;16(6):900-912. doi: 10.2174/1570179416666190704112904.
Triazoles are a class of aza-heterocycles with broad spectrum of biological importance. The synthetic tunability of the triazole moiety allows for the development of new pharmacophores with applications as drugs to contend with the burden of cancer.
In this study, we aimed to develop a series of N-aryltriazole and N-acridinyltriazole molecular hybrids and evaluate their potential as anticancer agents.
The triazole derivatives (1-10) were synthesized via a tandem nucleophilic substitution of aryl chlorides with sodium azide followed by 1,3-dipolar cycloaddition of the resulting organic azides with terminal/internal alkynes. From terminal alkynes, the well established copper(I) catalyzed azide-alkynes 1,3- dipolar cycloaddition, a premier example of click chemistry, was employed to access the 1,4-regioisomers of N-benzyl-1H-1,2,3-triazoles and N-acridynyl-1H-1,2,3-triazoles. All the compounds thus synthesized were characterized by 1D and 2D NMR spectroscopy and high resolution mass spectrometry.
Thermally controlled 1,3-dipolar cycloaddition was used to deliver N-aryl-1H-1,2,3-triazoles with 1,4,5-substitution on the triazole framework. The unprecedented high regioselectivity promoted by the sterically-strained silylated 1,4,5-trisubstituted moiety 4a offers a useful synthetic precursor with the silyl group being a synthetic handle for further structural elaboration to the desired 1,(4),5-di(tri)substituted 1,2,3- triazoles. Notably, anticancer evaluation revealed good cytotoxic activities of the novel acridinyltriazole hybrids (6-10) at micromolar concentrations in the range of 12.5 µM-100 µM against cervical cancer HeLa, kidney cancer HEK293, lung cancer A549 and leukemic MT4 cancer cell lines (p < 0.05).
A series of novel triazole-based acridine hybrids have been developed as potential leads for the development of multifaceted anticancer agents.
三唑是一类具有广泛生物学重要性的氮杂环化合物。三唑部分的合成可调性使得能够开发新的药效基团,作为应对癌症负担的药物。
在本研究中,我们旨在开发一系列N - 芳基三唑和N - 吖啶基三唑分子杂化物,并评估它们作为抗癌剂的潜力。
通过芳基氯化物与叠氮化钠的串联亲核取代反应,随后将所得有机叠氮化物与末端/内炔进行1,3 - 偶极环加成反应,合成三唑衍生物(1 - 10)。对于末端炔烃,采用成熟的铜(I)催化叠氮化物 - 炔烃1,3 - 偶极环加成反应(点击化学的一个主要例子)来制备N - 苄基 - 1H - 1,2,3 - 三唑和N - 吖啶基 - 1H - 1,2,3 - 三唑的1,4 - 区域异构体。通过一维和二维核磁共振光谱以及高分辨率质谱对所有合成的化合物进行表征。
热控1,3 - 偶极环加成反应用于在三唑骨架上提供具有1,4,5 - 取代的N - 芳基 - 1H - 1,2,3 - 三唑。空间位阻较大的甲硅烷基化1,4,5 - 三取代部分4a促进了前所未有的高区域选择性,提供了一种有用的合成前体,其中甲硅烷基基团是用于进一步结构修饰以得到所需的1,(4),5 - 二(三)取代的1,2,3 - 三唑的合成手柄。值得注意的是,抗癌评估显示新型吖啶基三唑杂化物(6 - 10)在12.5 μM - 100 μM的微摩尔浓度范围内对宫颈癌HeLa、肾癌HEK293、肺癌A549和白血病MT4癌细胞系具有良好的细胞毒性活性(p < 0.05)。
已开发出一系列新型基于三唑的吖啶杂化物,作为开发多方面抗癌剂的潜在先导化合物。